Inovio Pharma, Qiagen To Develop Next Gen Sequencing Companion Diagnostic For VGX-3100

Inovio Pharmaceuticals Inc. (INO) and Qiagen N.V. (QGEN) announced Wednesday their collaboration to develop next generation sequencing or NGS companion diagnostic for Inovio's VGX-3100 for advanced cervical dysplasia.

The companies are extending their partnership for the development of liquid biopsy-based companion diagnostic products based on NGS technology to complement INOVIO's therapies.

The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100, INOVIO's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus or HPV.

VGX-3100 is INOVIO's late-stage DNA immunotherapy candidate. It is currently in two Phase 3 trials (REVEAL 1 and REVEAL 2), with the potential to become the first non-surgical treatment for advanced pre-cancerous cervical lesions associated with the virus (HPV-16 and HPV-18).

QIAGEN's bioinformatic expertise will further increase the predictive power of INOVIO's preliminary biomarker signature - and the assay will now be developed for use on the Illumina NextSeq 550Dx platform, the first development based on a partnership QIAGEN and Illumina signed in October 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT